Cadrenal Therapeutics, Inc.
CVKD
$5.17
-$0.02-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.35M | 9.70M | 9.33M | 7.88M | 6.75M |
| Depreciation & Amortization | 6.90K | 6.70K | 6.70K | 6.80K | 1.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.46M | 14.67M | 14.40M | 13.13M | 10.96M |
| Operating Income | -13.46M | -14.67M | -14.40M | -13.13M | -10.96M |
| Income Before Tax | -13.24M | -14.39M | -14.11M | -12.83M | -10.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.24 | -14.39 | -14.11 | -12.83 | -10.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.24M | -14.39M | -14.11M | -12.83M | -10.65M |
| EBIT | -13.46M | -14.67M | -14.40M | -13.13M | -10.96M |
| EBITDA | -13.45M | -14.67M | -14.39M | -13.13M | -10.96M |
| EPS Basic | -6.70 | -8.83 | -9.70 | -10.07 | -9.55 |
| Normalized Basic EPS | -4.19 | -5.52 | -6.06 | -6.30 | -5.97 |
| EPS Diluted | -6.70 | -8.83 | -9.70 | -10.07 | -9.55 |
| Normalized Diluted EPS | -4.19 | -5.52 | -6.06 | -6.30 | -5.97 |
| Average Basic Shares Outstanding | 7.97M | 7.02M | 6.08M | 5.19M | 4.41M |
| Average Diluted Shares Outstanding | 7.97M | 7.02M | 6.08M | 5.19M | 4.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |